Healthcare
Live Price
Offline$1.60
+0.00% today
1Y Change
-27.27%
Window
Jun 26, 2025 โ Jun 24, 2026
Coverage: 256 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genscript Biotech Corporation (GNNSF) is a Healthcare stock with a market cap of $3.83B and listed on OTC. The stock last traded around $1.60 and down 27.3% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +61.6%, EPS growth of -117.9%, a dividend yield of 0.0%. What stands out right now is revenue +61.6%, EPS -117.9%, free cash flow +434.4% with operating margin 26.6% and ROIC 5.6%. Valuation is more restrained than many high-expectation growth names at price/sales 4.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GNNSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+61.6% vs +7.6% peer median
Operating Margin
Above sector median
+26.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +61.6% and EPS is at -117.9%, with operating margin around 26.6%.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GNNSF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GNNSF Max Drawdown
-46.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for GNNSF and SPY.

Company Overview
Genscript Biotech Corporation
Other OTC
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.